Ring Containing Patents (Class 514/559)
-
Publication number: 20120122816Abstract: The invention relates to reducing, preventing or reversing organ damage, reducing and/or preventing stem cell damage and/or death, enhancing organ preservation and/or survival, or enhancing stem cell preservation and/or survival comprising administering a compound of formula A, a compound of any one of formulae 1-49 or I-III, a lipoxin compound, an oxylipin compound, or a combination of aspirin and an omega-3 fatty acid.Type: ApplicationFiled: February 5, 2010Publication date: May 17, 2012Applicant: Resolvyx Pharmaceuticals, Inc.Inventor: Per Gjorstrup
-
Publication number: 20120115954Abstract: Embodiments of this invention relate to a composition containing both benzoyl peroxide and a retinoid. Additionally, it relates to the treatment of acne vulgaris by applying an aqueous gel comprising BPO and a retinoid.Type: ApplicationFiled: January 18, 2012Publication date: May 10, 2012Applicant: MEDICIS PHARMACEUTICAL CORPORATIONInventors: Mitchell S. Wortzman, Waranush Jitpraphai, Manzer Durrani
-
Publication number: 20120114566Abstract: This invention provides new lipoxin analogs, compositions containing analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease with compositions containing COX-2 inhibitors. Further, the invention provides methods for preventing systemic diseases beyond theoral cavity that are related to periodontal disease using the composition containing lipoxin analogs, COX-2 inhibitors, or both.Type: ApplicationFiled: January 9, 2012Publication date: May 10, 2012Applicants: TRUSTEES OF BOSTON UNIVERSITY, UNIVERSITY OF SOUTHERN CALIFORNIA, BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Thomas E. Van Dyke, Nicos A. Petasis, Charles N. Serhan
-
Patent number: 8173831Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.Type: GrantFiled: July 8, 2009Date of Patent: May 8, 2012Assignee: Catabasis Pharmaceuticals, Inc.Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Jesse J. Smith
-
Publication number: 20120108658Abstract: Disclosed is an ophthalmic composition which is characterized by containing (A) a vitamin A, (B) a polyoxyethylene polyoxypropylene glycol, and (C) an oil component that is selected from the group consisting of castor oil, soybean oil, sesame oil, peanut oil, olive oil, almond oil, wheat germ oil, corn oil, rapeseed oil, sunflower oil, purified lanolin and gel hydrocarbon.Type: ApplicationFiled: June 29, 2010Publication date: May 3, 2012Inventors: Akito Odaka, Chieko Inoue, Manabu Hattori, Nobuhito Tabuchi
-
Patent number: 8163800Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.Type: GrantFiled: July 28, 2009Date of Patent: April 24, 2012Assignee: Blanchette Rockefeller Neurosciences InstituteInventors: Thomas J. Nelson, Daniel L. Alkon
-
Publication number: 20120095097Abstract: Disclosed is an ophthalmic composition containing (A) not less than 50,000 units/100 mL of vitamin A, (B) not less than 0.4 W/V % of a polyoxyethylene polyoxypropylene glycol, and (C) trometamol.Type: ApplicationFiled: June 25, 2009Publication date: April 19, 2012Inventors: Nobuhito Tabuchi, Chieko Inoue, Manabu Hattori, Miyuki Miyake, Hazuki Tsutsui
-
Patent number: 8158681Abstract: The present invention relates to new methoxylated aromatic compounds. It also relates to novel compositions comprising methoxylated aromatic compounds as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.Type: GrantFiled: February 13, 2007Date of Patent: April 17, 2012Assignee: DSM IP Assets B.V.Inventors: Daniel Raederstorff, Joseph Schwager, Goede Schueler
-
Publication number: 20120087904Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.Type: ApplicationFiled: December 15, 2011Publication date: April 12, 2012Applicant: AmDerma Pharmaceuticals, LLCInventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Morgan, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Publication number: 20120065232Abstract: The photostabilizing electronic excited state energy—particularly singlet state energy from retinoid compounds—has been found to be readily transferred to (accepted by) ?-cyanodiphenylacrylate compounds having an alkoxy radical in the four (para) position (hereinafter “alkoxycrylenes”) on one of the phenyl rings having the formula (I): wherein one of R1 and R2 is a straight or branched chain C1-C30 alkoxy radical, preferably C1-C8, more preferably methoxy, and the non-alkoxy radical R1 or R2 is hydrogen; and R3 is a straight or branched chain C1-C30 alkyl radical, preferably C2-C20. The alkoxycrylene compounds of formula (I) significantly increase the photostability of retinoid compounds in a composition by at least 3-fold.Type: ApplicationFiled: October 27, 2011Publication date: March 15, 2012Applicant: HALLSTAR INNOVATIONS CORP.Inventors: Craig A. Bonda, Anna Pavlovic, Jean Zhang
-
Publication number: 20120064135Abstract: The present invention relates to the preparation of compositions comprising benzoyl peroxide, with or without other additional active ingredients. The process involves introducing benzoyl peroxide, along with any other active ingredients present, into a fatty substance that contains and protects the ingredients that would otherwise be unstable when in contact with one another. The composition is designed to allow all ingredients to become available for skin contact or skin absorption when the fatty substance softens and/or melts as the composition is applied to the skin. The benzoyl peroxide may be pre-micronized to a particle distribution size of about d90 of 0.1 to 150 microns, preferably d90 of 10 to 15 microns.Type: ApplicationFiled: August 16, 2011Publication date: March 15, 2012Applicant: Norac PharmaInventors: Daniel Levin, Arthur Harms
-
Publication number: 20120046354Abstract: A method for treating or preventing oral cavity mucosal disorders, comprising a step of providing a lozenge containing an antioxidant selected from the group of Vitamin A, Vitamin C, Vitamin E; and other ingredients and a step of placing the lozenge within the oral cavity for a period of time required for dissolution of the lozenge.Type: ApplicationFiled: August 18, 2010Publication date: February 23, 2012Inventor: Eli D. Ehrenpreis
-
Publication number: 20120040025Abstract: Methods for reducing the risk of or treating a disorder associated with fluid and/or salt retention in a patient are described. The methods include administering to the patient an agent selected from: a) an agent that reduces sodium absorption in the intestine; b) an agent that increases anion secretion in the intestine; or c) an agent that both reduces sodium absorption in the intestine and increases anion secretion in the intestine.Type: ApplicationFiled: April 23, 2008Publication date: February 16, 2012Inventors: Mark G. Currie, Daniel P. Zimmer
-
Publication number: 20120041029Abstract: Substantially non-porous polymeric microparticles comprising a hydrophobic polymer and a plasticizer, and containing therein a bioactive or bioinactive agent.Type: ApplicationFiled: October 17, 2011Publication date: February 16, 2012Applicants: DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES LIMITEDInventors: Arutla Srinivas, Harshal P. Bhagwatwar, Vakati Venkat Arvind, Saravana Perumal, Vemula Sathya Narayana, Mandavalli Srirama Sarveswara Rao, Venkateswarlu Vobalaboina, Nookaraju Venkata Sreedharala
-
Patent number: 8114910Abstract: A composition is provided which comprises an acidic component, generally fulvic acid, having a molecular weight not exceeding 20,000 Daltons and a low content of the elements aluminum, mercury, cadmium, chromium and lead. The acidic component is preferably carbohydrate derived and preferably using a wet oxidation process.Type: GrantFiled: April 26, 2007Date of Patent: February 14, 2012Assignee: Pfeinsmith S.A. (Pty) Ltd.Inventors: Earle John Loxton, Rudolph Johannes Malan, Stefan Coetzee
-
Patent number: 8114453Abstract: A synergistically heat stable therapeutically active triglyceride and cholesterol controlling oil composition including the usually highly unsaturated Eicosa Pentaenoic Acid (EPA) and Docosa Hexaenoic Acid (DHA). The invention avoids limitations of presently available impure sources of EPA/DHA such as fish oil, algae and the like and provides for a synergistically stable edible oil formulation involving the Eicosa Pentaenoic Acid and Docosa Hexaenoic acid of at least 50% to less than 100% purity in a free of any encapsulated/protected form in combination with synergistically stability contributing oil constituents/ingredients. The invention also provides for benefit applications/uses of the surprising and unexpected heat stability of the beneficial actives EPA and DHA. The invention is therefore directed to serve in possible provision of variety of alternative media including heat stable media for regular consumption of EPA/DHA and provide for maintenance of safe and healthy lifestyle.Type: GrantFiled: March 11, 2005Date of Patent: February 14, 2012Assignee: Recon Oil Industries Private LimitedInventor: Nirmal Sen
-
Patent number: 8115023Abstract: Benzolipoxin analogs, methods of their preparation and pharmaceutical compositions containing the compounds are provided. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease and abnormal cell proliferation.Type: GrantFiled: February 23, 2010Date of Patent: February 14, 2012Assignee: University of Southern CaliforniaInventor: Nicos A. Petasis
-
Publication number: 20120034205Abstract: The present disclosure provides a method for treating stroke by administering to a subject an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C (PKC) activator followed by administration of at least one PKC activator for a duration of treatment. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone; and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are kits comprising rTPA and a PKC activator for treating stroke.Type: ApplicationFiled: July 8, 2011Publication date: February 9, 2012Inventor: Daniel L. Alkon
-
Publication number: 20120035141Abstract: The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.Type: ApplicationFiled: October 11, 2011Publication date: February 9, 2012Applicant: ESPERION THERAPEUTICS, INC.Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
-
Patent number: 8106094Abstract: This invention relates to methods and compositions for treating and ameliorating skin conditions including post inflammatory hyperpigmentation (PIH). More particularly, this invention relates to compositions containing certain natural extracts, salicylic acid, and natural or synthetic retinoids. The composition was clinically proven to reduce PIH.Type: GrantFiled: July 30, 2004Date of Patent: January 31, 2012Assignee: Johnson & Johnson Consumer Companies, Inc.Inventors: Archana Sah, Victoria Dole, Glenn Nystrand, Miri Seiberg, Jue-Chen Liu, Ellen Kurtz
-
Patent number: 8101795Abstract: According to the present invention, there is provided a process for preparing corosolic acid comprising the steps of (1) dissolving crude extract of Japanese loquat leaves in alkali and aqueous alcohol and (2) applying the solution to a nonpolar adsorption resin to obtain corosolic acid.Type: GrantFiled: December 27, 2007Date of Patent: January 24, 2012Assignees: Kenko Corporation, Tokiwa Phytochemical Co., Ltd.Inventors: Naoaki Yoshida, Chihiro Mori, Tsutomu Sasaki
-
Publication number: 20120015001Abstract: The present invention relates to a methods and compositions for the treatment of and management of symptoms for thyroid eye disease. The methods include administering to a patient having thyroid eye disease an agent that interferes with hyaluronan synthesis in an amount that is effective to inhibit hyaluronan synthesis in a retro-ocular space. The pharmaceutical compositions hat includes a carrier suitable for ophthalmic delivery and an agent that interferes with hyaluronan synthesis. Combination therapies are also disclosed.Type: ApplicationFiled: May 3, 2011Publication date: January 19, 2012Applicant: UNIVERSITY OF ROCHESTERInventors: Richard P. Phipps, Naxin Guo, Steven Feldon
-
Publication number: 20120010288Abstract: A method of protecting a retinal neuronal cell by administering an effective amount of a prostaglandin F2? derivative to a patient. A method of preventing or treating an eye disease associated with retinal neuronal cell damage by administering a therapeutically effective amount of a prostaglandin F2? derivative to a patient.Type: ApplicationFiled: September 2, 2011Publication date: January 12, 2012Applicants: SANTEN PHARMACEUTICAL CO., LTD., ASAHI GLASS COMPANY, LIMITEDInventors: Naruhiro Ishida, Atsushi Shimazaki
-
Patent number: 8093293Abstract: This invention relates to methods and compositions for treating and ameliorating skin conditions including acne, rosacea and wrinkling caused by photodamage or intrinsic aging. More particularly, this invention relates to compositions containing certain natural extracts and natural or synthetic retinoids.Type: GrantFiled: September 10, 2003Date of Patent: January 10, 2012Assignee: Johnson & Johnson Consumer Companies, Inc.Inventors: Miri Seiberg, Jue-Chen Liu, Violetta Iotsova
-
Patent number: 8093417Abstract: This invention provides new lipoxin analogs, compositions containing analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease with compositions containing COX-2 inhibitors. Further, the invention provides methods for preventing systemic diseases beyond theoral cavity that are related to periodontal disease using the composition containing lipoxin analogs, COX-2 inhibitors, or both.Type: GrantFiled: September 28, 2010Date of Patent: January 10, 2012Assignees: Trustees of Boston University, Brigham and Women's Hospital, Inc., University of Southern CaliforniaInventors: Thomas E. Van Dyke, Nicos A. Petasis, Charles N. Serhan
-
Publication number: 20110318351Abstract: Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.Type: ApplicationFiled: September 12, 2011Publication date: December 29, 2011Inventor: Ivan Bergstein
-
Publication number: 20110319352Abstract: The invention relates in part to the discovery that certain CRAMs, such as schweinfurthin A, target OSBPs (a family of oxysterol binding proteins). Because OSBPs have been shown to be integral to atherosclerosis and Alzheimer's disease (AD), one aspect of the invention relates to the use of CRAMs, or a pharmaceutically acceptable salt, biologically active metabolite, solvate, hydrate, prodrug, enantiomer or stereoisomer thereof, in the treatment and/or prevention of atherosclerosis, Alzheimer's disease and related disorders. Another aspect of the invention relates to novel derivatives of CRAMs, or a pharmaceutically acceptable salt, biologically active metabolite, solvate, hydrate, prodrug, enantiomer or stereoisomer thereof, for the treatment and/or prevention of atherosclerosis, Alzheimer's disease and related disorders. Another aspect of the invention relates to the use of an immobilized CRAMs, such as OSW-I, to aid in screening of compounds to identify additional OSBP binders.Type: ApplicationFiled: December 11, 2009Publication date: December 29, 2011Applicant: President and Fellows of Harvard CollegeInventors: Matthew D. Shair, Anthony Burgett, D. Ryan Anderson
-
Publication number: 20110312915Abstract: The present invention is concerned with novel cosmetic or pharmaceutical compositions. More particularly, the invention is concerned with novel cosmetic or pharmaceutical compositions for treating or preventing any symptoms caused by negative developments of the physiological homeostasis of healthy skin, as well as for the promotion of hair growth and protection from hair loss.Type: ApplicationFiled: September 1, 2011Publication date: December 22, 2011Applicant: DSM IP ASSETS B.V.Inventor: Raphael Beumer
-
Publication number: 20110300083Abstract: Personal care formulations containing alkyl ketal esters having the structure wherein a is 0 or an integer of 1 to 12; b is 0 or 1; R2 is a divalent C1-8 group optionally substituted with up to 5 hydroxyl groups; and R1 is C1-6 alkyl.Type: ApplicationFiled: May 10, 2011Publication date: December 8, 2011Applicant: SEGETIS, INC.Inventors: Dorie J. YONTZ, Lee Richard RIETH, Nicholas MORANTE, Irwin PALEFSKY
-
Publication number: 20110294737Abstract: Platelets are induced to proliferate, form extensions and produce daughter cells by various methods, including culturing platelets under thrombocytopenic conditions. Expansion of platelet cell numbers increases the storage life of platelets. Modulation of RT activity can be used to produce new daughter platelets. Therefore, the invention provides a new therapeutic use for RT inhibitors that can now be used for treatment of thrombocytopenia and related disorders. Likewise, application of soluble protein factor that may be secreted and/or released by platelets cultured under thrombocytopenic conditions may also be used as a therapeutic agent to increase platelet numbers.Type: ApplicationFiled: October 7, 2009Publication date: December 1, 2011Inventors: Hansjorg Schwertz, Robert C. Blaylock, Larry W. Kraiss, Guy A. Zimmerman, Andrew S. Weyrich
-
Patent number: 8066971Abstract: This invention provides novel compositions and methods for the specific and/or preferential delivery of an effector (e.g. a drug or label) to an epithelial cell (e.g. a pulmonary epithelium). The compositions comprise an adipocyte differentiation-related protein (ADRP) attached to an effector thereby forming a chimeric moiety. The chimeric moiety is preferentially delivered to epithelial cells.Type: GrantFiled: April 3, 2006Date of Patent: November 29, 2011Assignee: Los Angeles Biomedical Reseach Institute at Harbor UCLA Medical CenterInventors: John S. Torday, Virender K. Rehan
-
Publication number: 20110288153Abstract: In certain embodiments this invention pertains to the discovery that inhibition of the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) inhibits the aging process. Accordingly, in certain embodiments, methods are provided for inhibiting/slowing aging. The methods typically involve administering to a mammal an agent that inhibits the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) in an amount sufficient to inhibit expression or activity of EIF4A, where the agent is not resveratrol.Type: ApplicationFiled: November 18, 2009Publication date: November 24, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jing Huang, Rui Hao, Brett Eugene Lomenick, Nao Jonai, Simon Diep
-
Publication number: 20110275715Abstract: The present application provides a method for treating a retinal disease in a patient in need thereof, which comprises administering at least three drops of an ophthalmic composition comprising a fatty acid derivative as an active ingredient in an eye of the patient per day.Type: ApplicationFiled: April 12, 2011Publication date: November 10, 2011Applicant: R-TECH UENO, LTD.Inventors: Yukihiko MASHIMA, Ryuji UENO
-
Patent number: 8053003Abstract: The present invention relates to the use of a plant oil product as an agent for increasing the synthesis of skin lipids, especially the lipids of the epidermal skin barrier, in or for the preparation of a cosmetic, pharmaceutical or dermatological composition. The invention also relates to a method for cosmetic treatment with a cosmetic, pharmaceutical or dermatological composition for increasing the synthesis of skin lipids, especially the lipids of the epidermal skin barrier, and to the use of the plant product as a food additive.Type: GrantFiled: July 20, 2009Date of Patent: November 8, 2011Assignee: Laboratoires ExpanscienceInventors: Philippe Msika, Antoine Piccirilli
-
Patent number: 8053471Abstract: The invention relates to the use of long chain polyunsaturated fatty acids for the manufacture of a nutritional composition for feeding infants of a mother who suffered from a metabolic disorder during pregnancy and to a corresponding composition. Said composition comprises a n-3 polyunsaturated fatty acid fraction containing at least 0.1 wt docosahexaenoic acid (DHA) based on total weight of the lipid, at least 0.01 wt % n-3 docosapentaenoic acid (DPAn-3) based on total weight of the lipid, and at least 0.01 wt. % eicosapentaenoic acid (EPA) based on total weight of the lipid, wherein the sum of DHA, DPAn-3 and EPA is below 1 wt. % of total lipid.Type: GrantFiled: November 11, 2005Date of Patent: November 8, 2011Assignee: N.V. NutriciaInventors: Bernd Stahl, Günther Boehm, Christopher Beermann, Johan Garssen
-
Publication number: 20110269691Abstract: A method of treating a hypopigmentary condition in a subject comprising administering to the subject an amount of SOX9 sufficient to treat melanoma is disclosed. The hypopigmentary condition can be a result of surgery, trauma or vitiligo. A method of treating a hyperpigmentary condition in a subject comprising administering to the subject an amount of inhibitor of SOX9 activity sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising administering to the subject an amount of SOX9 sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising increasing the amounts of retinoic acid and SOX9 in the subject by amounts sufficient to treat melanoma. A method of treating melanoma in a subject comprising administering to the subject an amount of prostaglandin D2 (PGD2) and retinoic acid (RA) sufficient to treat cancer.Type: ApplicationFiled: August 15, 2008Publication date: November 3, 2011Inventors: Vincent J. Hearing, Thierry Passeron
-
Patent number: 8043626Abstract: The novel antimicrobial composition is disclosed including from about 60 to 95% of a lipophilic polar solvent such as propylene glycol, ethylene glycol, or isopropanol and from about 0.5 to 5% of a mixture of C8 to C14 fatty acids. Other constituents of the present invention may include water, an alcohol (such as ethanol or propanol) or a mixture thereof. Also disclosed is a novel method of killing harmful microbes on the udder of a milk-producing animal using the above-mentioned composition.Type: GrantFiled: February 2, 2009Date of Patent: October 25, 2011Assignee: GEA Farm Technologies, Inc.Inventors: Alejandro O. Dee, Charles D. Gradle
-
Publication number: 20110251144Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/?-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/?-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/?-catenin pathway in a subject is also discussed.Type: ApplicationFiled: September 16, 2009Publication date: October 13, 2011Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, UNIVERSITY OF WASHINGTONInventors: Randall T. Moon, Travis L. Biechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass
-
Publication number: 20110251242Abstract: The photostabilizing electronic excited state energy—particularly singlet state energy from resveratrol compounds—has been found to be readily transferred to (accepted by) ?-cyanodiphenylacrylate compounds having an alkoxy radical in the four (para) position (hereinafter “alkoxycrylenes”) on one of the phenyl rings having the formula (I): wherein one of R1 and R2 is a straight or branched chain C1-C30 alkoxy radical, preferably C1-C8, more preferably methoxy, and the non-alkoxy radical R1 or R2 is hydrogen; and R3 is a straight or branched chain C1-C30 alkyl radical, preferably C2-C20. The alkoxycrylene compounds of formula (I) significantly increase the photostability of resveratrol compounds in a composition by at least 3-fold and as much as 10-fold or greater. The ability of the alkoxycrylene compounds to stabilize the resveratrol compound is concentration dependent, with the amount of resveratrol photostabilization increasing with the concentration of the alkoxycrylene compound.Type: ApplicationFiled: April 5, 2011Publication date: October 13, 2011Applicant: HALLSTAR INNOVATIONS CORP.Inventors: Craig A. Bonda, Anna Pavlovic, Jean Zhang
-
Patent number: 8030352Abstract: A method of producing a retinyl ester compound comprising subjecting a composition comprising retinyl or a retinyl ester and a fat or oil of animal or vegetable origins to enzyme catalysed trans-esterification in solvent free conditions to produce a retinyl ester.Type: GrantFiled: November 6, 2008Date of Patent: October 4, 2011Assignee: Unilever Home & Personal Care USA, division of Conopco, Inc.Inventors: John Anthony Bosley, Clive Roderick Harding, Christopher Rawlins, Julia Sarah Rogers, Ian Richard Scott
-
Patent number: 8026280Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy. Carboxylic acid-containing compounds having a terminal cyclic moiety, a carboxylic acid group, and a C3-12 hydrocarbon chain optionally containing at least one double bond, at least one triple bond, or at least one double bond and one triple bond linking the cyclic moiety and the carboxylic acid group are inhibitors of histone deacetylase.Type: GrantFiled: December 26, 2001Date of Patent: September 27, 2011Assignee: Errant Gene Therapeutics, LLCInventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L Wiech
-
Publication number: 20110212157Abstract: The present invention describes systems and methods for treating disorders and/or conditions associated with the dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, and/or actinic keratosis. Methods generally involve administering nanoemulsions (e.g., nanoparticle compositions) comprising at least one therapeutic agent, such as botulinum toxin. In some embodiments, nanoemulsions are prepared, e.g., by high pressure microfluidization, and comprise a particle size distribution exclusively between 10 nm and 300 nm.Type: ApplicationFiled: June 26, 2009Publication date: September 1, 2011Applicant: ANTERIOS, INC.Inventors: Jonathan Edelson, Timothy Kotyla, Boke Zhang
-
Patent number: 8008282Abstract: The present invention is directed to methods for the prevention or inhibition of angiogenesis. The method is accomplished by the administration of an effective amount of 15-epi-16-(para-fluoro)-phenoxy-lipoxin A4, LXA4, 15-epi-LXA4 or 15-R/S-methyl, LXA4 and pharmaceutically acceptable salts, esters, amides, carboxylic acids, or prodrugs thereof, to a subject in need thereof. As a consequence of the action of the therapeutic agent, angiogenesis is prevented or inhibited in the subject.Type: GrantFiled: September 8, 2005Date of Patent: August 30, 2011Assignee: The Brigham & Women's Hospital, Inc.Inventors: Charles N. Serhan, Iolanda M. Fierro
-
Publication number: 20110206626Abstract: A skin care product comprising from about 0.001% to about 10% of a retinoid, in combination with 0.0001% to about 50% of a combination of retinoid boosters.Type: ApplicationFiled: April 29, 2011Publication date: August 25, 2011Applicant: CONOPCO, INC., D/B/A UNILEVERInventors: Stewart Paton Granger, Ian Richard Scott, Robert Mark Donovan, Susanne Teklits Iobst, Lisa Licameli
-
Publication number: 20110190395Abstract: The present disclosure relates to lipid compounds of general formula (I) wherein R1 is chosen from a C10-C22 alkyl group, a C10-C22 alkenyl group having 1-6 double bonds, and a C10-C22 alkynyl group having 1-6 triple bonds; R2 and R3 are the same or different and may be selected from different substituents; Y is chosen from sulphur, sulfoxide, and sulfone; and X is a carboxylic acid or a derivative thereof, a carboxylic ester, a carboxylic anhydride, or a carboxamide; or a pharmaceutically acceptable salt, complex, or solvate thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and methods of using such compounds such as for treating diseases related to cardiovascular, metabolic, and/or inflammatory diseases.Type: ApplicationFiled: July 13, 2009Publication date: August 4, 2011Inventors: Anne Kristin Holmeide, Ragnar Hovland, Morten Brændvang
-
Publication number: 20110190307Abstract: The present invention provides zebrafish based methods for the identification of compounds potentially useful in the treatment of motor neuron degenerative diseases (MNDDs), compounds identified by these methods and compositions, methods and medicaments for treating MNDDs.Type: ApplicationFiled: June 25, 2009Publication date: August 4, 2011Inventors: Catherina G. Becker, Thomas Becker
-
Publication number: 20110177156Abstract: Disclosed are sterol-modified amphiphilic lipid compounds having two or more hydrophobic tails of which at least one is a sterol. Also disclosed are the processes for the synthesis of these compounds, compositions comprising such compounds, and the use of such compounds in delivery of an agent of interest, e.g., therapeutics, imaging agents, contrast materials for ultrasound applications, vaccines, biosensors, nutritional supplements and skin care products.Type: ApplicationFiled: November 10, 2008Publication date: July 21, 2011Inventors: Francis C. Szoka, JR., Zhaohua Huang
-
Publication number: 20110172299Abstract: Disclosed herein are compounds represented by a formula: Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: May 11, 2009Publication date: July 14, 2011Applicant: ALLERGAN, INC.Inventors: Todd Gac, David W. Old
-
Publication number: 20110150981Abstract: A compound of formula (I) for use in the treatment of a disease of the immune system; wherein R is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 50 carbon atoms; R1 is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 40 carbon atoms; each of R2, Wand R4 is independently selected from an optionally-substituted alkylene, alkenylene, alkynylene, arylene, arylalkylene or alkylarylene moiety having from 1 to 40 carbon atoms; each of X, Y and Z is independently selected from an optionally-substituted alkylene, alkenylene, alkenylene, arylene, alkylarylene, cycloalkylene, ketone, ester, amide, imide, imine, thioether, ether, thioester and thioketone; and P is selected from hydrogen, an alkyl group, a sugar residue, or a metal, phosphonium or ammonium species; wherein at least one of X, Y and Z includes a moiety selected from cyclopropyl, C=A, C-AH and C-OR5; wherein R5 is alkyl or haloalkyl, and A is O, SType: ApplicationFiled: April 22, 2009Publication date: June 23, 2011Applicant: Bangor UniversityInventors: Mark Stephen Baird, Juma' a Raheem Najeem Al-Dulayymi, Cornelias Theunissen, Gani Koza, Seppe Vander Beken, Johan Adriann March Grooten
-
Publication number: 20110150955Abstract: Products and methods are disclosed for reducing the production of unwanted odors from the pudendum.Type: ApplicationFiled: September 2, 2010Publication date: June 23, 2011Inventor: Shannon Elizabeth Klingman